LSX2026

R&D

LSX2026: Endogenous tissue restoration in vascular disease –...

Paulo Neves, CMO of Xeltis, discusses transformative implants that enable the natural creation of living and long-lasting vessels.

R&D

LSX2026: Non-opioid pain relief and pharma positivity, with ...

Mike Cooke, CEO of AmacaThera, spoke with pharmaphorum at the LSX World Congress, including about non-opioid pain relief.

Oncology

LSX2026: Addressing adult eye cancer, with Roi Raz

Roi Raz, CEO of ReBio Pharma, discusses injectable, bioresorbable sustained release delivery for ophthalmic therapeutics at LSX 2026.

R&D

Interview at LSX 2026 with Alexander Gebauer

LSX2026: On a therapeutic vision for ocular disease, with Al...

Alexander Gebauer, co-founder & executive chairman of Galimedix Therapeutics, discusses transforming treatment of major neurodegenerative eye diseases

LSX2026: Endogenous tissue restoration in vascular disease –...

LSX2026: Non-opioid pain relief and pharma positivity, with ...

LSX2026: Addressing adult eye cancer, with Roi Raz

LSX2026: On a therapeutic vision for ocular disease, with Al...

Lundbeck preps for key bexicaserin data around year-end

Discover a new era of healthcare panel engagement: Grounded ...

LSX2026

Editor's Picks